Skip to main content

Advertisement

SpringerLink
Log in

Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

Sexually transmitted infections and chronic inflammation have been associated with an increased risk of prostate cancer. Inflammatory mediators, such as cytokines and free radicals, have been hypothesized to play a role.

Methods

To explore the role of inflammation in prostate cancer risk further, we examined the association between pre-diagnostic serum levels of interleukin-16 (IL-16), an important pleiotropic cytokine, and prostate cancer risk among 932 Caucasian cases and 942 controls and 154 African-American cases and 302 controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum IL-16 was quantified using enzyme-linked immunoassay. Logistic regression was used to estimate associations between IL-16 and prostate cancer risk, separately by race.

Results

Although no association between IL-16 and prostate cancer overall was observed among Caucasians (p = 0.27), a significantly increased risk of high-grade prostate cancer, defined as Gleason ≥ 7 (phet = 0.02), was observed with increasing levels of IL-16 (OR3rd vs. 1st tertile = 1.37, 95% CI 1.04–1.81, ptrend = 0.02). We also discovered a significant interaction between IL-16 and history of gonorrhea (p = 0.04). Among Caucasian men with a history of gonorrhea, elevated IL-16 levels were associated with an increased risk of prostate cancer (OR3rd vs. 1st tertile = 3.64, 95% CI 1.14–11.6) but no association was seen among those without a history of gonorrhea (OR3rd vs. 1st tertile = 1.06, 95% CI 0.83–1.34). No associations were observed among African-Americans.

Conclusions

This study found evidence that higher pre-diagnostic IL-16 levels may be associated with increased risk of high-grade disease, supporting inflammation as potential mechanism by which sexually transmitted diseases may increase risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60(1):78–83

    Article  PubMed  Google Scholar 

  2. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15(1):93–99

    Article  PubMed  Google Scholar 

  3. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A (2014) Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 38(4):329–338

    Article  PubMed  Google Scholar 

  4. Lian WQ, Luo F, Song XL, Lu YJ, Zhao SC (2015) Gonorrhea and prostate cancer incidence: an updated meta-analysis of 21 epidemiologic studies. Med Sci Monit 21:1902–1910

    PubMed  Google Scholar 

  5. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J et al (2015) Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol Lett 9(3):1307–1312

    Article  PubMed  Google Scholar 

  6. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ (2015) Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 21(4):756–762

    Article  CAS  PubMed  Google Scholar 

  7. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2):130–135

    CAS  PubMed  Google Scholar 

  8. Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7(1):169–170

    CAS  PubMed  Google Scholar 

  9. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77(3):219–225

    Article  PubMed  Google Scholar 

  10. Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7):1680–1691

    Article  CAS  PubMed  Google Scholar 

  11. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA (2001) Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 158(5):1767–1773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Woenckhaus J, Fenic I (2008) Proliferative inflammatory atrophy: a background lesion of prostate cancer? Andrologia 40(2):134–137

    Article  CAS  PubMed  Google Scholar 

  13. Wang W, Bergh A, Damber JE (2009) Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 69(13):1378–1386

    Article  PubMed  Google Scholar 

  14. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37(4):404–412

    Article  CAS  PubMed  Google Scholar 

  15. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K et al (2002) Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 167(5):2267–2270

    Article  PubMed  Google Scholar 

  16. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA et al (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43(2):164–175

    Article  PubMed  Google Scholar 

  17. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR et al (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23(5):847–856

    Article  Google Scholar 

  18. Glass WG, Sarisky RT, Vecchio AM (2006) Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 26(8):511–520

    Article  CAS  PubMed  Google Scholar 

  19. Cruikshank WW, Kornfeld H, Center DM (2000) Interleukin-16. J Leukoc Biol 67(6):757–766

    Article  CAS  PubMed  Google Scholar 

  20. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M (1997) Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. Aids 11(4):485–491

    Article  CAS  PubMed  Google Scholar 

  21. Scala E, D’Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM et al (1997) C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 158(9):4485–4492

    CAS  PubMed  Google Scholar 

  22. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H (1998) Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 37(12):1334–1337

    Article  CAS  PubMed  Google Scholar 

  23. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW (2002) Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11(3):181–185

    Article  CAS  PubMed  Google Scholar 

  24. Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, Stein G (2001) Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology 40(4):474–475

    Article  CAS  PubMed  Google Scholar 

  25. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA et al (2008) Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58(5):1465–1474

    Article  CAS  PubMed  Google Scholar 

  26. Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A et al (2004) Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol 75(2):101–106

    Article  CAS  PubMed  Google Scholar 

  27. Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H et al (2009) The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 30(2):295–299

    Article  CAS  PubMed  Google Scholar 

  28. Comperat E, Roupret M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A et al (2010) Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 70(15):1622–1627

    Article  CAS  PubMed  Google Scholar 

  29. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S et al (2000) Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 100(1):63–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gohagan JK, Prorok PC, Hayes RB, Kramer BS (2000) The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl):251 s-272 s

    Google Scholar 

  32. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N et al (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 Suppl):349s–355s

    Article  CAS  PubMed  Google Scholar 

  33. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB et al (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41(10):1055–1057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF et al (2008) Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomark Prev 17(9):2374–2381

    Article  CAS  Google Scholar 

  35. Tuzova M, Richmond J, Wolpowitz D, Curiel-Lewandrowski C, Chaney K, Kupper T et al (2015) CCR4 + T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma 56(2):440–449

    Article  CAS  PubMed  Google Scholar 

  36. Yellapa A, Bitterman P, Sharma S, Guirguis AS, Bahr JM, Basu S et al (2014) Interleukin 16 expression changes in association with ovarian malignant transformation. Am J Obstet Gynecol 210(3):272.e1-10

    Article  PubMed  Google Scholar 

  37. Purzycka-Bohdan D, Szczerkowska-Dobosz A, Zablotna M, Wierzbicka J, Piotrowska A, Zmijewski MA et al (2016) Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease. PLoS ONE 11(10):e0165577

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nischwitz S, Faber H, Samann PG, Domingues HS, Krishnamoorthy G, Knop M et al (2014) Interferon beta-1a reduces increased interleukin-16 levels in multiple sclerosis patients. Acta Neurol Scand 130(1):46–52

    Article  CAS  PubMed  Google Scholar 

  39. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW et al (2005) Anti-IL-16 therapy reduces CD4 + T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 79(5):680–693

    Article  CAS  PubMed  Google Scholar 

  40. Paalani M, Lee JW, Haddad E, Tonstad S (2011) Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis 21(2):142–149

    PubMed  PubMed Central  Google Scholar 

  41. Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV et al (2014) Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes 38(11):1416–1422

    Article  CAS  Google Scholar 

  42. Fisher G, Hyatt TC, Hunter GR, Oster RA, Desmond RA, Gower BA (2012) Markers of inflammation and fat distribution following weight loss in African-American and white women. Obesity 20(4):715–720

    Article  CAS  PubMed  Google Scholar 

  43. Stowe RP, Peek MK, Cutchin MP, Goodwin JS (2010) Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A Biol Sci Med Sci 65(4):429–433

    Article  PubMed  Google Scholar 

  44. Contreras-Sesvold C, Revenis BD, O’Connor FG, Deuster PA (2015) Association of plasma heat shock protein 70, interleukin 6, and creatine kinase concentrations in a healthy, young adult population. J Biomark 2015:967120

    PubMed  PubMed Central  Google Scholar 

  45. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA (2006) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(11):2160–2166

    Article  Google Scholar 

  46. Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK (2005) Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case–control study in Wayne County, Michigan. Cancer Causes Control 16(3):263–273

    Article  PubMed  Google Scholar 

  47. Pelucchi C, Talamini R, Negri E, Franceschi S, La Vecchia C (2006) Genital and urinary tract diseases and prostate cancer risk. Eur J Cancer Prev 15(3):254–257

    Article  PubMed  Google Scholar 

  48. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269

    Article  PubMed  PubMed Central  Google Scholar 

  49. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E (2014) Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease—the 2001–2008 National Health and Nutrition Examination Survey. Prostate 74(5):561–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Elzanaty S, Rezanezhad B, Borgquist R (2016) Association between PSA Levels and biomarkers of subclinical systemic inflammation in middle-aged healthy men from the general population. Curr Urol 9(3):148–152

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA

    Amy Moore, Wen-Yi Huang, Roni Falk & Sonja I. Berndt

  2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA

    Kim Danforth

  3. Protein Expression Laboratory, Cancer Research and Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

    Allison Meade & Rachel Bagni

Authors
  1. Amy Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen-Yi Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kim Danforth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roni Falk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Allison Meade
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rachel Bagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sonja I. Berndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy Moore.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 29 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moore, A., Huang, WY., Danforth, K. et al. Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 29, 455–464 (2018). https://doi.org/10.1007/s10552-018-1012-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-018-1012-5

Keywords

Search

Navigation